Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Oramed PharmaceuticalsNuCanaOncternal TherapeuticsLarimar TherapeuticsGalera Therapeutics
SymbolNASDAQ:ORMPNASDAQ:NCNANASDAQ:ONCTNASDAQ:LRMRNASDAQ:GRTX
Price Information
Current Price$9.28$4.42$6.26$12.84$7.52
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.31.51.71.61.6
Analysis Score3.53.44.53.53.5
Community Score3.12.63.42.12.1
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.01.71.7
Earnings & Valuation Score0.00.00.60.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$13.33$17.50$15.20$29.00$17.00
% Upside from Price Target43.68% upside295.93% upside142.81% upside125.86% upside126.06% upside
Trade Information
Market Cap$272.55 million$214.35 million$309.02 million$197.33 million$187.82 million
Beta1.980.921.660.651.89
Average Volume790,876516,9231,731,71568,95467,944
Sales & Book Value
Annual Revenue$2.71 millionN/A$2.42 millionN/AN/A
Price / Sales100.57N/A127.69N/AN/A
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$1.40 per share$2.52 per share$0.93 per share$17.22 per share$2.81 per share
Price / Book6.63N/A6.73N/AN/A
Profitability
Net Income$-11,510,000.00$-27,340,000.00$-34,190,000.00$-45,410,000.00$-51,930,000.00
EPS($0.56)($0.84)($1.56)N/A($16.31)
Trailing P/E RatioN/AN/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-424.76%N/A-746.10%N/AN/A
Return on Equity (ROE)-45.93%-35.90%-150.58%-38.70%-151.01%
Return on Assets (ROA)-30.33%-32.56%-91.87%-31.40%-60.72%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio8.93%12.48%3.01%20.82%8.79%
Quick Ratio8.93%12.48%3.01%20.82%8.79%
Ownership Information
Institutional Ownership Percentage6.03%84.13%10.79%88.76%75.41%
Insider Ownership Percentage16.10%N/A10.90%5.10%19.30%
Miscellaneous
EmployeesN/A27122832
Shares Outstanding29.37 million48.50 million49.36 million15.37 million24.98 million
Next Earnings Date7/6/2021 (Estimated)5/18/2021 (Estimated)5/6/2021 (Estimated)5/6/2021 (Estimated)5/11/2021 (Estimated)
OptionableOptionableNot OptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ...Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent ...
apnews.com - March 12 at 5:40 PM
Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent AccomplishmentsGalera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments
finance.yahoo.com - March 11 at 7:25 AM
Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare ConferenceGalera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
finance.yahoo.com - March 10 at 8:15 AM
We Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth CarefullyWe Think Galera Therapeutics (NASDAQ:GRTX) Needs To Drive Business Growth Carefully
finance.yahoo.com - February 19 at 11:40 AM
Is GRTX A Good Stock To Buy Now?Is GRTX A Good Stock To Buy Now?
finance.yahoo.com - December 7 at 8:45 PM
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business UpdatesGalera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
finance.yahoo.com - November 10 at 10:09 AM
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare ConferenceGalera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
finance.yahoo.com - November 3 at 12:54 PM
AC Immunes Alzheimers Setback, And Other News: The Good, Bad And Ugly Of BiopharmaAC Immune's Alzheimer's Setback, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - October 30 at 7:36 AM
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination ...Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination ...
apnews.com - October 29 at 12:10 AM
Galera down 6% on disappointing data on lead drug in pancreatic cancerGalera down 6% on disappointing data on lead drug in pancreatic cancer
seekingalpha.com - October 27 at 11:45 PM
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic CancerGalera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanced Pancreatic Cancer
finance.yahoo.com - October 27 at 6:45 PM
Lianluo Smart, Galera Therapeutics leads healthcare gainers; BioSig Technologies, Aileron Therapeutics among major losersLianluo Smart, Galera Therapeutics leads healthcare gainers; BioSig Technologies, Aileron Therapeutics among major losers
seekingalpha.com - October 26 at 11:33 AM
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic CancerGalera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer
finance.yahoo.com - October 23 at 8:46 PM
Galera Therapeutics Inc.Galera Therapeutics Inc.
barrons.com - October 23 at 3:42 PM
Dosing underway for Galera Therapeutics GC4711 in early-stage lung cancer studyDosing underway for Galera Therapeutics' GC4711 in early-stage lung cancer study
seekingalpha.com - October 22 at 2:17 PM
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung CancerGalera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer
finance.yahoo.com - October 22 at 9:13 AM
How Many Galera Therapeutics, Inc. (NASDAQ:GRTX) Shares Do Institutions Own?How Many Galera Therapeutics, Inc. (NASDAQ:GRTX) Shares Do Institutions Own?
finance.yahoo.com - October 20 at 11:09 AM
Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic CancerGalera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer
benzinga.com - September 22 at 8:32 AM
Dosing is underway for Galeras lead asset in mid-stage COVID-19 studyDosing is underway for Galera's lead asset in mid-stage COVID-19 study
seekingalpha.com - September 16 at 1:29 PM
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19
finance.yahoo.com - September 16 at 8:28 AM
Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitGalera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
finance.yahoo.com - September 14 at 9:08 AM
Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic CancerGalera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBRT for Locally Advanced Pancreatic Cancer
finance.yahoo.com - September 8 at 8:13 AM
Galera Therapeutics: Reasonable Valuation With Fast Track And Breakthrough DesignationGalera Therapeutics: Reasonable Valuation With Fast Track And Breakthrough Designation
seekingalpha.com - September 7 at 11:16 AM
Galera Therapeutics, Inc. Common Stock (GRTX)Galera Therapeutics, Inc. Common Stock (GRTX)
nasdaq.com - August 14 at 12:00 PM
Galera Therapeutics EPS beats by $0.01Galera Therapeutics EPS beats by $0.01
seekingalpha.com - August 10 at 11:06 AM
DateCompanyBrokerageAction
2/15/2021Oramed PharmaceuticalsAegisReiterated Rating
2/9/2021Oramed PharmaceuticalsNational SecuritiesInitiated Coverage
12/3/2020Oramed PharmaceuticalsAlliance Global PartnersInitiated Coverage
7/13/2020Oramed PharmaceuticalsHC WainwrightReiterated Rating
9/11/2019Oramed PharmaceuticalsLADENBURG THALM/SH SHInitiated Coverage
7/16/2018Oramed PharmaceuticalsB. RileyDowngrade
3/30/2021NuCanaWilliam BlairReiterated Rating
10/22/2020NuCanaTruistInitiated Coverage
9/21/2020NuCanaOppenheimerReiterated Rating
8/21/2020NuCanaPiper SandlerBoost Price Target
7/29/2020NuCanaCowenReiterated Rating
11/15/2019NuCanaPiper Jaffray CompaniesLower Price Target
8/21/2019NuCanaCitigroupSet Price Target
3/30/2021Oncternal TherapeuticsBrookline Capital ManagementReiterated Rating
3/30/2021Oncternal TherapeuticsBrookline Capital AcquisitionInitiated Coverage
2/23/2021Oncternal TherapeuticsNorthland SecuritiesInitiated Coverage
2/10/2021Larimar TherapeuticsJMP SecuritiesInitiated Coverage
12/16/2020Galera TherapeuticsCredit Suisse GroupUpgrade
10/28/2020Galera TherapeuticsSmith Barney CitigroupBoost Price Target
12/2/2019Galera TherapeuticsBTIG ResearchInitiated Coverage
12/2/2019Galera TherapeuticsBank of AmericaInitiated Coverage
(Data available from 4/14/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.